+1 (855) PLE.XISION (753.9474) info@plexision.com
  • Dedicated To Individual Health
    Personalized medicine and drug development in organ transplantation and immunological disorders.
  • PleximmuneTM
    Predicts the risk of acute cellular rejection after liver or intestine transplantation in children.
  • Cell-Based Biomarkers
    Combined drug-biomarker development for immunological disorders.
  • PlexCMVTM
    Measuring cell mediated immunity to Cytomegalovirus

In the News:

  • PlexCMVTM, measuring cell-mediated immunity to cytomegalovirus....
  • Some CMV-seronegative recipients harbor protective cellular immunity to CMV....
 

Plexision’s first patented product, the PleximmuneTM test, predicts the risk of acute cellular rejection after liver or intestine transplantation in children

Learn More +

Pleximmune FAQs +

The PleximarkTM blood test assesses the likelihood of acute cellular rejection after renal transplantation.

Learn More +

show all Pleximark FAQs

Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post- marketing.      

Learn More +

      

Immuno-Oncology is a rapidly growing area of tumor therapy that fights cancer               

  • by recruiting the patient’s immune system, or

  • with drugs that are based on immune mechanisms.

Learn More +

PlexCMVTM is a blood test to measure the level of cellular immunity to Cytomegalovirus (CMV). Decreased anti-CMV immunity increases the risk of CMV infection.   

Learn More +

PlexEBVTM is a lab developed blood test to measure the level of cellular immunity to Epstein-Barr virus (EBV). Decreased anti-EBV immunity increases the risk of EBV infection.  

Learn More +

Immune deficiency can impair cellular or antibody-mediated immune responses and cause recurrent infections and cancers. Our test panel evaluates T-cell dysfunction using mitogen and antigen stimulation.  

Learn More +